Health IT Startup: Shivom
Unlocking the genomic code to usher in a new era of medical technology.
The core Shivom team came together after numerous meetings at blockchain and genomics conferences. During these, we frequently reached conclusions on how to solve the current issues in the medical domain, by combining the bleeding-edge of blockchain technology with genomic sequencing.
The fuel that powers the Shivom platform is community involvement. We aim to forge meaningful partnerships with medical groups around the world, which can then interact directly with the Shivom blockchain and its users.
Shivom’s target audience? Everyone. Big data analysis requires big data sets, and in the case of the platform, the more users having sequenced and uploaded their genomic data means that there is a larger pool of information to draw from. Of course, a large part of the offering is the secure storage of this information is securely stored, and the individuals to whom it belongs can choose to monetize it by allowing access to innovators in the medical space.
Who are your competitors?
There are few competitors in this space – somewhat reassuring, as our vision is to unite players in the medical field. However, Nebula is a blockchain platform also occupying the genetic niche.
How your company differentiates itself from the competition and what differentiates Shivom?
Simply put, Shivom is a blockchain storage and analytics platform for genetic information. On top of its core functionality, it also enables users to profit from their data by sharing it with institutions.
Differentiating it from similar projects is its magnitude – a global reach and a unique classification system for genomic ID. On the roadmap are integrated AI protocols for in-depth insights.
Shivom is still in its infancy, although we anticipate that, in moving forward, revenue will be generated by pharmaceutical companies wishing to use data in their research. Additional revenue will stem from a range of apps and services (to glean insights on one’s uploaded data) and the sale of sequencing kits.